Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly M Chin

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Circulation. Heart Failure|February 22, 2023
Disentangling the Pulmonary Capillary Wedge Pressure From the Pulmonary Artery Pressure as the Hemodynamic Underpinning of BendopneaJennifer T Thibodeau, Goutham Ravipati, David D Pham, et al.
Cardiology and Therapy|March 7, 2024
Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS DatasetRichard Channick, Kelly M Chin, Vallerie V McLaughlin, et al.
Advances in Therapy|November 19, 2025
Characteristics, Treatment Patterns and Outcomes of Patients with Pulmonary Arterial Hypertension by Race and Ethnicity Using Real-World Data from the Combined OPUS/OrPHeUS StudiesLana D Melendres-Groves, Richard N Channick, Kelly M Chin, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 2, 2021
Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERENick H Kim, Anna R Hemnes, Murali M Chakinala, et al.
The European Respiratory Journal|September 10, 2024
MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH studyMarc Humbert, Paul M Hassoun, Kelly M Chin, et al.
Pulmonary Therapy|January 6, 2024
Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS StudiesNick H Kim, Kelly M Chin, Vallerie V McLaughlin, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|October 1, 2023
Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)Vallerie McLaughlin, Harrison W Farber, Kristin B Highland, et al.
Respiratory Research|February 4, 2021
Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III studyHans Klose, Kelly M Chin, Ralf Ewert, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 15, 2025
Corrigendum to ''Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)'' [J Heart Lung Transplant 43 (2024) 272-283]Vallerie McLaughlin, Harrison W Farber, Kristin B Highland, et al.
The European Respiratory Journal|November 13, 2025
Long-term safety and tolerability of frespaciguat: INSIGNIA-PAH extensionMarc Humbert, Paul M Hassoun, Kelly M Chin, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Circulation. Heart Failure|February 22, 2023
Disentangling the Pulmonary Capillary Wedge Pressure From the Pulmonary Artery Pressure as the Hemodynamic Underpinning of BendopneaJennifer T Thibodeau, Goutham Ravipati, David D Pham, et al.
Cardiology and Therapy|March 7, 2024
Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS DatasetRichard Channick, Kelly M Chin, Vallerie V McLaughlin, et al.
Advances in Therapy|November 19, 2025
Characteristics, Treatment Patterns and Outcomes of Patients with Pulmonary Arterial Hypertension by Race and Ethnicity Using Real-World Data from the Combined OPUS/OrPHeUS StudiesLana D Melendres-Groves, Richard N Channick, Kelly M Chin, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 2, 2021
Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERENick H Kim, Anna R Hemnes, Murali M Chakinala, et al.
The European Respiratory Journal|September 10, 2024
MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH studyMarc Humbert, Paul M Hassoun, Kelly M Chin, et al.
Pulmonary Therapy|January 6, 2024
Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS StudiesNick H Kim, Kelly M Chin, Vallerie V McLaughlin, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|October 1, 2023
Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)Vallerie McLaughlin, Harrison W Farber, Kristin B Highland, et al.
Respiratory Research|February 4, 2021
Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III studyHans Klose, Kelly M Chin, Ralf Ewert, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 15, 2025
Corrigendum to ''Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)'' [J Heart Lung Transplant 43 (2024) 272-283]Vallerie McLaughlin, Harrison W Farber, Kristin B Highland, et al.
The European Respiratory Journal|November 13, 2025
Long-term safety and tolerability of frespaciguat: INSIGNIA-PAH extensionMarc Humbert, Paul M Hassoun, Kelly M Chin, et al.
Pageof 7